Countries China

WuXi Biologics attains leadership status in 2023 CDP Climate Change evaluation

  CDP runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impact. In 2023, more than...

 March 06, 2024 | News

YolTech's Gene Editing Therapy YOLT-201 Advances to Phase I Clinical Trials for Rare Genetic Disease

YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, announced the Center for Drug Evaluation ...

 March 05, 2024 | News

Teva Partners with Jiangsu Nhwa to Enhance AUSTEDO® Access in China

  “Nhwa has deep neuro-psychiatry expertise and capabilities, from research and development to commercialization,” commented Theodor Wee,...

 February 28, 2024 | News

Everest Medicines, Kezar Get China NMPA Nod for Lupus Nephritis Trial

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced that the Center for Drug Evaluation (CDE) of China's Natio...

 February 27, 2024 | News

Enveric Biosciences Divests Cancer-Targeting Cannabinoid IP to Focus on Mental Health Therapeutics

  Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology firm at the forefront of developing neuroplastogenic small-molecule therapeutics, an...

 February 26, 2024 | News

Immunofoco Achieves Historic Dual IND Approval for Groundbreaking EpCAM CAR-T Therapy

  EpCAM, known for its presence in circulating tumor cells (CTCs) and high expression in primary and metastatic lesions of gastrointestinal tumors, r...

 February 26, 2024 | News

Hox Therapeutics and Vernalis Enter Collaboration to Advance Oncology Drug Discovery

Hox Therapeutics Ltd, a pioneering biotechnology company dedicated to developing targeted cancer therapies, and Vernalis (R&D) Ltd, a renowned subsidia...

 February 22, 2024 | News

Innovent's IBI311 Clears Phase 3 Hurdle for Thyroid Eye Disease with Promising Results

The trial also successfully met its key secondary endpoints, including the overall response rate, the percentage of subjects achieving a clinical activity ...

 February 20, 2024 | News

Biocytogen and Gilead Forge Landmark Collaboration to Harness Fully Human Antibody Library for Therapeutic Innovations

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a leading biotechnology company,  announced a significant coll...

 February 20, 2024 | News

Jacobio Gains China CDE Approval for Phase III SHP2 and KRAS G12C Inhibitor Trial

This approved study in China is a randomized active controlled phase III trial design to evaluate the efficacy and safety of JAB-3312 in combinat...

 February 19, 2024 | News

Brii Biosciences Secures Intellectual Property Rights for HBV Treatment from VBI Vaccines

Brii Biosciences Limited ("Brii Bio"), a leader in developing innovative treatments for diseases with significant unmet needs, has announced a strategic ac...

 February 14, 2024 | News

Cathay Biotech and 3P.COM Forge Groundbreaking Joint Venture to Propel Sustainable Composite Innovations

In a strategic move towards sustainable innovation, Cathay Biotech Inc. of China and 3P.COM Co. Limited of South Korea have signed a landmark joint venture...

 February 09, 2024 | News

Innovent Biologics Advances Novel Weight Management Drug Mazdutide with NDA Acceptance in China

  This groundbreaking achievement marks mazdutide as the first GLP-1R/GCGR dual agonist to successfully complete Phase 3 trials in support of an NDA ...

 February 08, 2024 | Regulatory

Nordic Bioscience Partners with Roche for PRO-C3 Biomarker in China

The PRO-C3 biomarker is relevant for drug development in particularly chronic diseases with a fibrotic component e.g., non-alcoholic steatohepatitis (NASH,...

 February 06, 2024 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close